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Abstract
Background: Our previous studies showed that the expression of the monocyte-chemoattractant protein (MCP)-1, a 
chemokine, which triggers the infiltration and activation of cells of the monocyte-macrophage lineage, is abrogated in 
human papillomavirus (HPV)-positive premalignant and malignant cells. In silico analysis of the MCP-1 upstream region 
proposed a putative p53 binding side about 2.5 kb upstream of the transcriptional start. The aim of this study is to 
monitor a physiological role of p53 in this process.
Results: The proposed p53 binding side could be confirmed in vitro by electrophoretic-mobility-shift assays and in vivo 
by chromatin immunoprecipitation. Moreover, the availability of p53 is apparently important for chemokine regulation, 
since TNF-α can induce MCP-1 only in human keratinocytes expressing the viral oncoprotein E7, but not in HPV16 E6 
positive cells, where p53 becomes degraded. A general physiological role of p53 in MCP-1 regulation was further 
substantiated in HPV-negative cells harboring a temperature-sensitive mutant of p53 and in Li-Fraumeni cells, carrying 
a germ-line mutation of p53. In both cases, non-functional p53 leads to diminished MCP-1 transcription upon TNF-α 
treatment. In addition, siRNA directed against p53 decreased MCP-1 transcription after TNF-α addition, directly 
confirming a crosstalk between p53 and MCP-1.
Conclusion: These data support the concept that p53 inactivation during carcinogenesis also affects immune 
surveillance by interfering with chemokine expression and in turn communication with cells of the immunological 
compartment.
Background
Chemokines play a crucial role in innate and adaptive
immunity by attracting and activating specific subsets of
effector leukocytes, cells from the monocyte/macrophage
lineage as well as natural killer cells. Accordingly, these
kinds of exoproteins are involved in many physiological
processes such as cell proliferation, apoptosis, tumor
metastasis and host defense [1]. The monocyte-chemoat-
tractant protein-1 (MCP-1), a well-known member of the
CC subgroup chemokine family, has been linked with
chronic inflammatory diseases [2,3] antitumor immunity
[4,5], atherosclerosis [6] and cervical cancer [7-9].
Like many other human malignancies, development of
cervical cancer is a multi-step process, which is initiated
by the infection of "high-risk" types of human papilloma
viruses (HPV) such as HPV 16 or HPV 18. The trans-
forming potential is encoded by the open reading frames
E6 and E7. Both oncoproteins exert pleiotropic functions
on their host cells, such as inactivation of the major
tumour suppressors, p53 and retinoblastoma protein
(pRB), respectively [10]. Although it is believed that
deregulated viral oncogene expression is the first event
towards anogenital cancer, the immunological defense
mechanisms still have to be evaded so that progression
towards cervical cancer can take place [11]. Hence, con-
sidering cancer as a micro-evolutionary process [12],
"high risk" HPVs have developed several evasion or sub-
version strategies to escape immunological surveillance
[13].
Consistent with this notion is that cervical carcinoma
lines lack significant cytokine-inducible MCP-1 expres-
sion [7-9]. However, this insufficiency can be restored
after fusion with normal cells, resulting in somatic cell
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hybrids that are no longer tumorigenic when inoculated
into immunocompromised animals [14]. Notably, tum-
origenic segregants derived from such hybrids again
loose MCP-1 expression [9,15], indicating that abroga-
tion of chemokine expression may provide a selective
advantage for tumor progression [8]. This assumption is
also supported by in situ hybridization and immunohis-
tochemical studies, showing that MCP-1 expression and
infiltrating cells of the monocyte/macrophage lineage
were only detectable in premalignant precursor cells, but
absent in high-grade lesions of cervical cancer patients
[7,16,17].
Concerning MCP-1 expression, previous studies have
identified both the nuclear factor-kappa B (NFκB) and
the activator protein-1 (AP-1) as essential regulators of
MCP-1 transcription and its induction upon TNFα stim-
ulation [18-21]. TNF-α is a multifunctional cytokine that
is involved in many regulatory circuits such as cell cycle
control, interferon-β induction, inflammation and apop-
tosis [22-24]. Binding of TNF-α to its cognate receptors
(TNF-R1/-R2) particularly results in the activation of AP-
1 and NFκB [24,25]. On the other hand, TNF-α can also
induce p53 which modulates a variety of genes involved
in apoptosis, DNA repair and innate immunity [26-29].
TNF-α activates p53 via NFκB by binding to the corre-
sponding promoter [30], which is, however, counteracted
by the HPV-E6-mediated degradation of p53 through the
proteasomal pathway [31] or by p53 mutations in virus-
independent forms of human cancer [32].
In the present study, we demonstrate that p53 is
directly involved in the regulation of human MCP-1 tran-
scription. This supports the notion that p53 inactivation
and consequently MCP-1 down-regulation during HPV-
induced pathogenesis generates a selection advantage
during progression to cervical cancer, explaining the
often observed successive depletion of immunological
effector cells within late premalignant HPV-positive
lesions.
Methods
Cell lines and cytokine treatment
Primary human foreskin keratinocytes (HFKs) were
immortalized with E6, E7 or E6/E7 oncogenes of HPV16
[33] and maintained in Keratinocyte Growth Medium
(PromoCell, Heidelberg, Germany). Early and late pas-
sage MDAH041 Li-Fraumeni cell lines [34-36], non-tum-
origenic somatic cell hybrids ("444") between HeLa and
IMR-90, their tumorigenic segregants ("CGL3") [14] and
the human glioblastoma cell line A172 were cultured as
previously described [22]. Stable Hep3B clones [37] car-
rying puromycin resistance alone ('BT2E') or in combina-
tion with stable expression of the temperature sensitive
mutant p53val135 ('4Bv') were cultivated in Dulbecco's
modified Eagle's medium, supplemented with 10% fetal
calf serum, 1% penicillin/streptomycin and additionally 2
μg/ml puromycin (Sigma) except during experiments. For
cytokine treatment, the cells were incubated with 250 U/
ml TNF-α (Strathmann Biotec AG) for different periods
of time as indicated in the figure legends.
Transfection
A172 cells (1 × 105) were transfected with Effectene
Transfection Reagent (Qiagen) according to the manufac-
turer's instructions using 1 μg pSUPER-p53 for the for-
mation of siRNA targeting p53 transcripts or the
respective empty vector [38] as described in the figure
legend.
Lentiviral shRNA-mediated knockdown of p53 in HPV E7 
immortalized keratinoytes
Cells were infected either with Lentiviruses encoding
short hairpin shRNA targeting p53 (Santa Cruz Biotech-
nology, sc-29435-v) or scrambled controls (sc-108080)
according to the manufacturer's protocol. Briefly, infec-
tion was carried out at a multiplicity of infection (MOI)
of 5 in serum free growth medium containing 5 μg/ml of
polybrene at 37°C and 5% CO2. After 4 hours, serum con-
tained medium was added and the cells were cultured for
48 hours. After 2 day post-infection, infected cells were
s e l ect ed  i n  t h e  p r es e n c e  o f  p u r o m y c i n  ( 5  μ g / m l )  f o r  5
days. RT-PCR analyses for p53 knockdown efficiency and
MCP-1 transcription was performed as described below.
SDS-PAGE and Western blotting
Whole cellular proteins were separated in 10-12% sodium
dodecyl sulfate (SDS) polyacrylamide gels (PAGE) and
electrophoresed to PVDF membranes (Immobilon-P,
Millipore Corporation). The following antibodies were
used: p53 (DO-1) from Santa Cruz, phospho-Thr180/
Tyr182 p38 MAPK (9211S) and p38 MAPK (9212) from
NEB. Equal protein transfer and loading was routinely
controlled by incubating the filters with a monoclonal
actin antibody (ICN Biomedicals).
Northern blotting
Total cellular RNA was isolated with the RNeasy kit (Qia-
gen) according to the instructions of the manufacturer. 4-
6 μg of RNA were separated on 1% agarose gels in the
presence of ethidium bromide under nondenaturing con-
ditions and transferred to GeneScreen Plus membranes
(DuPont, NEN). Specific probes for the hybridization
were labeled with [32P]dCTP (Amersham) by random
priming using HexaLabel Plus DNA Labeling Kit (Fer-
mentas). The filters were hybridized in 50% formamide,
10 U/ml tRNA, 5 × SSC, 0.1% Denhardt's-buffer, 50 mM
sodium phosphate-buffer, 1% SDS. Washing was per-
formed in 2 × SSC with 0.1% SDS at 68°C. Hybridized fil-
ters were exposed to high performance autoradiographyHacke et al. Molecular Cancer 2010, 9:82
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films. Densitometric quantification of band intensities
was performed using a ChemImager 5500 with software
(Alpha Innotech Corporation, San Leandro, California,
USA), analyzing signals within the linear range.
DNA hybridization probes
The full-length cDNA encoding the monocyte-chemoat-
tractant-protein-1 (MCP-1) [39] was obtained from the
American Type Culture Collection (Rockville, MD, USA).
The cDNA for p21 [40] was kindly provided by B.
Vogelstein (John Hopkins Institute, Baltimore, MD) via P.
Jansen-Dürr (University of Innsbruck, Austria). The plas-
mid pc-myc containing the third exon of the human c-
myc gene was kindly made available by G. Bornkamm
(Institut für Klinische Molekularbiologie, München, Ger-
many) [41]. The cDNA of human β-actin was a generous
gift from H. Bierhoff (DKFZ, Heidelberg).
Semiquantitative RT-PCR
Total cellular RNA was isolated using the RNeasy Kit
(Qiagen, Turnberry Lane, CA). For RT, 1 μg of DNase
treated RNA was prepared as described previously [22].
PCR was performed using Taq Polymerase (Promega)
according to the manufacturer's instructions using the
following primers: MCP-1 sense 5'-CAG ATG CAA TCA
ATG CCC CAG T-3'; MCP-1 antisense 5'-ATA AAA
CAG GGT GTC TGG GGA AAG C-3', IFN-β sense 5'-
GAT TCA TAT AGC ACT GGC TTG-3', IFN-β anti-
sense 5'-CTT CAG GTA ATG CAG AAT CC-3'. p53
sense 5'-AGA GCC ACC GTC CAG GGA GC-3' anti-
sense 5'-GGC AGT GAC CCG GAA GGC AG-3'. Condi-
tions for p53, MCP-1 and IFN-β PCR: 3 min at 94°C,
followed by 30 cycles (35 cycles were applied for MCP-1)
for 30 s at 94°C, 1 min at 58°C, 30 s at 72°C and 10 min at
72°C. GAPDH primers: sense 5'-TGG ATA TTG TTG
CCA TCA ATG ACC-3'; antisense 5'-GAT GGC ATG
GAC TGT GGT CAT G-3'; amplification was made as
previously described using 65°C of annealing tempera-
ture. The PCR products were analyzed on agarose gels.
Cell cycle analysis
Cells were harvested by trypsination, washed twice with
phosphate-buffered saline (PBS) and fixed overnight with
70% ethanol. After fixation and centrifugation, the cell
pellets were resuspended in DNA staining solution con-
taining DAPI (5 × 10-6 M) as the DNA dye and SR 101 (5
× 10-6M) as a protein counter stain as described by Stöhr
et al. [42]. Processing, cell cycle analysis of flow cytomet-
ric data were performed according to Dean and Jett [43].
Electrophoretic mobility shift assays with p53 isolated from 
insect cells
p53 proteins from human origin were expressed in High
Five™ insect cells and isolated as described previously
[44,45]. DNA binding experiments were performed in a
reaction mixture containing 60 ng of p53 protein, 2 nM of
the labeled probe and 20 nM of competitor tRNA in 25
mM Tris-HCl (pH 8.0), 5 mM EDTA, 1 mM DTT and 6%
glycerol. In control reactions without p53, the protein
storage buffer was added. For supershift analysis the mix-
tures were preincubated with the indicated antibodies for
30 min before addition of labeled DNA. Samples were
loaded onto a 4% native polyacrylamide gel and electro-
phoresed in 6.7 mM Tris-HCl (pH 8.0), 3.3 mM sodium
acetate and 2 mM EDTA. After electrophoresis gels were
dried and exposed to X-ray films. To obtain radioactive
DNA substrates, oligonucleotide #1 was end-labeled with
T4 polynucleotide kinase and [γ-32P] ATP and annealed
with unlabeled, complementary oligonucleotide #2. Dou-
ble-stranded DNA molecules were purified in 8% native
polyacrylamide gels. DNA concentrations were measured
by using DNA Dipsticks (Invitrogen). The following oli-
gonucleotides covering the wild-type p53-specific RGC,
RGC mutated and the MCP-1 p53-site were used: RGC-
#1: 5'-TCG AGT TGC CTG GAC TTG CCT GGC CTT
GCC TTT TC-3', RGC-#2: 5'-GAA AAG GCA AGG
CCA GGC AAG TCC AGG CAA CTC GA-3', mutRGC-
#1: 5'-TCG AGT TTA ATG GAC TTT AAT GGC CTT
TAA TTT TC-3', mutRGC-#2: 5'-GAA AAT TAA AGG
CCA TTA AAG TCC ATT AAA CTC GA-3', MCP-#1:
5'-AGA GAT GAC AAC TCC TTC CTG AAG TAG
AGA CAT GCT TCC AA-3', MCP-#2: 5'-TTG GAA
GCA TGT CTC TAC TTC AGG AAG GAG TTG TCA
TCT CT-3'. Monoclonal antibodies used for p53 super-
shift analyses were: DO-1 (Ab-6), PAb1801 (Ab-2), and
PAb421 (Ab-1) directed against the amino acids 21-25,
32-79, and 372-382, respectively (Calbiochem); ab9484
directed against GAPDH from Abcam.
Chromatin Immunoprecipitation
Experiments were performed with the chromatin immu-
noprecipitation (ChIP) assay kit (Upstate Biotechnology)
according to the manufacturer's instructions except that
the LiCl Immune Complex washing buffer was diluted 1:5
in H2O before use. 1 × 106 cells were used per immuno-
precipitation reaction mixture. Cells were crosslinked in
1% formaldehyde for 10 min, washed twice in PBS and
lysed in SDS lysis buffer (50 mM Tris-HCl, pH 8.1, 10
mM EDTA, and 1% SDS) and Complete protease inhibi-
tor cocktail (Roche) on ice for 10 min. The chromatin was
sonicated to an average length of 500-1000 bp. The soni-
cated cell supernatant was 10 fold diluted in ChIP dilu-
tion buffer (16.7 mM Tris-HCl, pH 8.1, 1.2 mM EDTA,
0.01% SDS, 1.1% Triton X-100 and Complete protease
inhibitor cocktail, Roche) and precleared by incubating
with salmon sperm DNA/protein A agarose-beads for 1 h
at 4°C. An aliquot of the diluted cell supernatant (5%) wasHacke et al. Molecular Cancer 2010, 9:82
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kept to quantitate the amount of DNA present in differ-
ent samples (input). The protein A agarose beads were
then pelleted and discarded, and the protein-chromatin
complexes were immunoprecipitated with an antibody
against p53 (8 μg, FL-393; Santa Cruz) or rabbit immuno-
globulin G (8 μg, IgG; Santa Cruz) at 4°C over night. Each
reaction mixture was then incubated with salmon sperm
DNA/protein A agarose beads for 1 h at 4°C. The protein
A agarose beads/antibody/chromatin complexes were
washed once with Low salt immune complex wash buffer
(20 mM Tris-HCl, pH 8.1, 150 mM NaCl, 0.1% SDS, 1%
Triton x-100 and 2 mM EDTA), once with High salt
immune complex wash buffer (20 mM tris-HCl, pH 8.1,
500 mM NaCl, 0.1% SDS, 1% Triton X-100 and 2 mM
EDT A), once in LiCl immune complex wash buffer (10
mM Tris-HCl, pH 8.1, 1 mM EDTA, 0.25 M LiCl, 1%
IGEPAL-CA630 and 1% deoxycholic acid,) and twice in
TE-buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). The
protein-chromatin complexes were eluted twice from the
protein A agarose beads by use of IP elution buffer (0.1 M
NaHCO3,1% SDS), followed by reverse cross-linking in
0.3 M NaCl at 65°C for 4 h. Each reaction mixture was
then incubated with 40 mM Tris-HCl, pH 7.4, 0.2 M
NaCl and 2 μl of 10 mg/ml Proteinase K at 45°C for 1 h.
Subsequently, the samples were purified by phenol-chlo-
roform extraction. PCR analysis of the isolated DNA frag-
ments used the following primer pairs: MCP-1 (295 bp
fragment primers) forward, 5'-GCAGAAGTGGGAG-
GCAGACA-3', and reverse 5'-GGCTTATAGACA
TCCTGTGGCATG-3', MCP-1 (nested primers) forward
5'-TTCTGATTCATACCCTTCACC TTCC-3' and
reverse 5'-GATAAAGCCACAATCCAGAGAAGGA-3'
p21 forward, 5'-CTGTGGCTC TGATTGGCTTT-3', and
reverse 5'-ACACAAGCACACATGCATCA-3'. PCR
reactions with the different primers gave rise to a single
specific product of the expected size. PCR products were
resolved on 2% agarose gels.
Results
MCP-1 expression in HPV16 E7 immortalized keratinocytes 
and detection of a p53 binding site within the enhancer 
region
Previously we have shown that in contrast to primary
human keratinocytes, MCP-1 expression and its induc-
ibility by TNF-α is lost during cellular immortalization by
HPV16 [8]. Conversely, using amphotropic retroviruses
that separately encode the oncoproteins of HPV16 (E6,
E7 and E6/E7, respectively), TNF-α is only inducing
MCP-1 in E7-positive keratinocytes, but not in cells
expressing either E6 alone or in conjunction with E7 (Fig.
1A). Since this correlates with the presence of p53 [33],
we monitored MCP-1 inducibility in E7-immortalized
keratinocytes after delivery of lentiviral vectors encoding
a specific short hairpin shRNA directed against p53. For
this purpose, cells were infected in parallel with a scram-
bled control and selected in the presence of a dominant
selection marker. As shown in Fig. 1B, knock-down of
p53 has a strong negative impact on MCP-1 induction
after TNF-α treatment, suggesting an involvement of p53
in MCP-1 gene regulation. Indeed, monitoring the
upstream region by in silico analysis, a potential p53
binding site within the MCP-1 promoter was predicted.
Fig. 1C schematically depicts the 5'-region of MCP-1
2.7-2.2 kb upstream from the transcriptional start site,
which is characterized by the presence of a prominent
DNAseI hypersensitive site (DHSS) when the
nucleosomal organization of the MCP-1 gene is exam-
ined [18]. By scanning the 5'-DHSS for additional DNA
binding motifs, a putative p53 binding sequence (5'-
tGACAAcTCCxxxxxxxxxxxxAGACATGCTT-3'),
located between AP-1 and NFκB binding sites, could be
detected. This sequence shows high homology (18 out of
20 bp) with the p53 consensus site (5'-(PuPuPuC(A/T)(T/
A)GPyPyPypY)n-3') and comprises two half-sites sepa-
rated by a spacer of 12 bp, which is within the normal
range between 0-13 bp [46].
To determine whether p53 can physically interact with
this sequence, electrophoretic mobility shift assays
(EMSAs) using a 41-mer double-stranded oligonucle-
otide encompassing the putative binding site in MCP-1
were performed. Human wild-type p53 protein was
obtained from baculovirus infected insect cells and p53-
DNA complex formation was verified using the
sequence-specific p53 recognition site from the ribo-
somal gene cluster repeat (RGC) as positive and a
mutated version as negative control [47]. As shown in Fig.
1D, both MCP-1 and RGC oligonucleotides form distinct
bands with the same mobility, indicating that similar p53-
DNA complexes were formed, while mutated RGC failed
to bind (left panel). To demonstrate the specificity of wild
type p53 in DNA-complex formation, supershift analyses
with monoclonal anti-p53 antibodies (DO-1, PAb1801,
and PAb421, respectively) were carried out. Addition of
DO-1 and PAb1801 antibodies caused retardation of p53-
DNA complexes, while BSA and purified monoclonal
antibody against GAPDH as controls did not. PAb421
slightly enhanced p53-DNA complex formation but did
not induce a supershift. This difference may be due to the
phosphorylation pattern of baculovirus derived p53,
since the PAb421 epitope only becomes exposed when
the Ser376 residue is dephosphorylated [48]. To further
ascertain the specificity, we analyzed the affinity of a
DNA-contact mutant (p53pro248) and a conformational
mutant of p53 (p53pro273) [49], which both failed to pro-
duce a gel shift (Fig. 1D, right panel). On the basis of the
in vitro binding studies, one can conclude that wild-typeHacke et al. Molecular Cancer 2010, 9:82
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p53 forms stable complexes with the in silico predicted
p53 binding site within the MCP-1 upstream regulatory
sequence.
Role of p53 in TNF-α-mediated MCP-1 induction
To further delineate the function of p53 in the regulation
of the MCP-1 gene, we used the p53 negative hepatocel-
lular carcinoma cell line Hep3B, stably co-transfected
with an expression plasmid encoding a murine tempera-
ture-sensitive mutant of p53 (p53val135) and a vector for
puromycin resistance ("4Bv") or with the resistance
marker alone ("BT2E"). Shifting the temperature of 4Bv
cell cultures to 32°C restores wild-type properties of p53
whereas at 37°C p53 is inactive [37].
Figure 1 MCP-1 expression in HPV16 immortalized human keratinocytes and in vitro binding activity of wild-type p53 at the MCP-1 regu-
latory region. (A) Upper panel: RT-PCR for MCP-1 and GAPDH in HPV16 E6-, E7-, and E6/7 immortalized human foreskin keratinocytes. Cells were 
treated with TNF-α (250 U/ml) (+) for 6 h. (-) untreated control. The RT-PCR products were separated on 1.5% agarose gel. Lower panel: Western blot 
analysis of p53. Cytosolic extracts (50 μg per lane) were separated in a 12% SDS-PAGE. Equal loading was confirmed using an actin specific antibody. 
(B) RT-PCR for MCP-1, p53 and GAPDH in E7-immortalized keratinocytes after lentiviral p53 shRNA delivery. Cells were treated as described in panel A. 
(C) Schematic overview of the MCP-1 gene. The region -2750 to -2150 bp upstream of the MCP-1 start site harbors two NFκB and one AP-1 binding 
site. The in silico identified putative p53 binding site (-2422/-2391) relative to NFκB and AP-1 is indicated. Black boxes: exon I-III; white box: polyadeny-
lation site (poly-A), (striped grey box): 3'-regulatory region. (D) Left panel: Electrophoretic mobility shift assay (EMSA): 60 ng of recombinant p53 pro-
tein was incubated with [32P]-labeled double-stranded oligonucleotides harboring the wild-type p53-specific RGC-site, the mutated version thereof 
and the putative MCP-1 p53 binding site, respectively. In addition, binding was also performed in the presence of 200 ng of BSA, anti-GAPDH, DO-1, 
PAb1801, or PAb421. The positions of free probe, DNA in complex with p53, and DNA in complex with p53 plus supershifting antibodies are indicated 
by arrows. (D) Right panel: EMSA: comparative binding analysis for wild-type p53 (wtp53) using specific RGC and non-specific RGC mutated versus 
MCP-1 DNA. DNA binding activities of wild-type p53 (wtp53), p53pro248 and p53pro273 mutants are indicated.
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As depicted in Fig. 2A, transcription of p21 mRNA was
strongly induced in 4Bv cells after the shift to 32°C, when
compared to the cells left at 37°C, independently of
whether TNF-α was added or not. In BT2E control cells,
however, no p21 induction was observed (Fig. 2B). This
clearly indicates that p53 in 4Bv cells was functionally
reconstituted at 32°C.
In order to test whether p53 in 4Bv cells affects MCP-1
gene regulation, the same filters were hybridized with a
MCP-1 cDNA probe. As shown in Fig. 2A, induction of
MCP-1 after stimulation with TNF-α was detectable in
4Bv cells, but only at 32°C. Induction was selective, since
the immediate-early gene c-myc (Fig. 2A) was not modu-
lated under these conditions. In contrast, induction of
MCP-1 was not detected in BT2E cells after temperature
shift and stimulation with TNF-α (Fig. 2B). This indicates
that reconstitution of p53 activity restores the inducibility
of MCP-1 transcription by TNF-α.
Cell cycle distribution and TNF-α signaling are not affected 
in 4Bv cells by temperature shift
Although activation of threshold levels of wild-type p53
and p21 does not induce growth arrest in 4Bv cells [37],
we wanted to exclude the possibility that increased MCP-
1 expression may simply result from a kind of synchroni-
zation effect, accumulating more cells in cell cycle phases
that can re-express MCP-1 upon TNF-α addition than a
non-synchronized cell population. However, flow cyto-
metric analyses of cells growing at different temperatures
revealed no significant changes in their percentage dis-
tributed in different phases of the cell cycle, indicating
that synchronization cannot account for the stronger
MCP-1 expression (Fig. 3A).
Moreover, to rule out that temperature-shifts may
affect TNF-α signaling, activation of p38 MAP kinase was
examined [50]. For this purpose, cells were cultivated at
32°C or 37°C, treated with TNF-α for different periods of
time and analyzed for p38 phosphorylation via immuno-
blotting. As presented in Fig. 3, there were equal amounts
of non-phosphorylated p38 (panel B), which became
phosphorylated with roughly the same kinetics after
TNFα addition, independently of the temperature shift
(panel C).
Induction of MCP-1 by TNF-α depends on p53 expression
To further prove a more general role of p53 in MCP-1
regulation, early passage immortalized cells from a Li-
Fraumeni patient were used. These fibroblasts initially
carry a germ-line mutation in one p53 allele [51]. After
longer in vitro cultivation, however, they spontaneously
immortalize at a high rate, with frequent somatic muta-
tions in the remaining wild-type allele of p53 [34,35]. As
demonstrated in Fig. 4A, cell cultures at passage 8 still
showed a significant MCP-1 induction after TNFα treat-
ment, which was strongly reduced when immortalized
cells at passage 160 were examined. The usage of the p53
specific DO-1 antibody illustrates that wt-p53 can still be
detected and induced by TNF-α in early, but not in late
passage cells (Fig. 4B), carrying a frameshift mutation at
amino acid position 175 (changing arginine to histidine)
[36,52,53].
Moreover, to prove the impact of endogenous p53
knockdown also in other cell systems, we used the glio-
blastoma cell line A172 (Fig. 4D), where similar to E7-
immortalized keratinocytes (see Fig. 1A, upper panel),
expression of MCP-1 can be strongly induced by TNF-α
[20]. After transient transfection with pSUPER-p53
which encodes a p53 specific siRNA [38] and subsequent
stimulation with TNF-α, suppression of p53 (Fig. 4C) and
a reduced MCP-1 transcription could be also discerned
(Fig. 4D). Taken together, these data prove the notion of a
wide-ranging involvement of p53 in MCP-1 inducibility
in different cell types.
p53 binding to the MCP-1 5'-regulatory region in vivo
To investigate whether p53 interacts with its binding site
within the MCP-1 enhancer also under in vivo condi-
tions, chromatin immunoprecipitation (ChIP) experi-
ments were carried out. For this purpose, we took again
advantage of the temperature-sensitive cell system shown
in Fig. 2A and 2B. 4Bv cells maintained at 37°C or shifted
to 32°C were incubated with TNF-α. After 5 hours,
treated and untreated controls were fixed with formalde-
hyde and DNA sheared samples were immunoprecipi-
tated with antibodies directed against p53. Controls
without antibodies or with antibodies against rabbit IgG
were included. The origin of the PCR-primers flanking
the p53 binding site is outlined in Fig. 5A. As shown in
Fig. 5B, MCP-1 chromatin was specifically immunopre-
c i p i t a t e d  w i t h  a n t i - p 5 3  a n t i b o d i e s  o n l y  f r o m  T N F - α
Figure 2 MCP-1 induction by TNF-α after reconstitution of wild-
type p53 activities. 4Bv (A) and BT2E (B) cells were cultivated at 37°C 
or shifted to 32°C overnight. Stimulation was done with TNF-α for 4 h 
or 6 h. Total cellular RNA was separated in a 1% agarose gel and trans-
ferred to a Gene screen Plus membrane. The filter was subsequently 
hybridized with a p21, MCP-1 and c-myc cDNA probe. The positions of 
the 28S and 18S ribosomal RNA are indicated.
ABHacke et al. Molecular Cancer 2010, 9:82
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treated cells cultivated at 32°C. In contrast, PCR amplifi-
cation covering the p53 binding site at the p21 promoter
shows a signal after shifting to 32°C, independently of
whether TNF-α was added or not. This indicates that, in
contrast to p21, p53 binds to the MCP-1 enhancer in vivo
in a TNF-α dependent manner.
Discussion
Studying MCP-1 in the context of HPV-induced carcino-
genesis, there is apparently a counterselection, which
favors the outgrowth of virus-positive cells lacking MCP-
1 expression [8,10]. Since high-risk HPVs are known to
degrade p53 via the proteasomal pathway [31] and p53 is
the most frequently mutated tumor suppressor gene in
human cancer [32], we anticipated a potential role of p53
in MCP-1 regulation. This idea was supported by the
observation that MCP-1 can only be induced by TNF-α in
human keratinocytes immortalized with HPV16 E7, but
not in cells carrying E6 alone or together with E7 (Fig.
1A). Hence, co-expression of MCP-1 and HPV16 E6
seems to be mutually exclusive.
The in silico predicted p53 binding site within the 5'-
regulatory region of MCP-1 (Fig. 1C) was first verified by
electro-mobility shift assays (EMSAs), showing complex
formation of wild-type but not mutant p53 (Fig. 1D). To
further define a p53 dependent mechanism of MCP-1 up-
regulation upon cytokine treatment, we used an experi-
mental model in which a temperature sensitive p53val135
variant of p53 can be reactivated from an inactive to an
active conformation, simply by shifting the temperature
[37]. As shown in Fig. 2A, only in cells where wild-type
p53 activity was reconstituted, MCP-1 expression could
be induced after incubation with TNF-α. This cannot be
attributed to dysfunctional signal transduction or weaker
TNFα binding to its cognate receptor after shifting the
cells to a lower temperature, since p38 MAP kinase phos-
Figure 3 Temperature shifting does not affect the cell cycle or TNF-α signaling. (A) 4Bv cells were maintained at 37°C or 32°C overnight, followed 
by treatment with or without TNF-α for 6 h. Flow-cytometric analysis was performed on DAPI/SR 101 stained cells to determine the percentage of 4Bv 
cells in different cell cycle phases (G1, S, G2/M). Mean values (columns) and standard deviations (bars) are given for three independent experiments. 
Steady state expression (B) and phosphorylation (C) of p38 MAP kinase was analyzed after treatment of 4Bv cells (at 37°C or 32°C) with TNF-α as indi-
cated. Total cellular protein (50 μg) was separated in a 12% SDS-PAGE gel. After electrotransfer, the filter was consecutively incubated with antibodies 
as indicated and re-probed with anti-actin antibody as loading-controls. (-): untreated control cells; (15')/(30')/(60'): cells treated with 250 U/ml of TNF-
α for the indicated time.
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phorylation almost followed the same kinetics (Fig. 3B
and 3C). Another advantage of this cell system is that p53
reactivation and subsequent p21 induction does not exert
a cell cycle arrest (Fig. 3A), most likely due to the pres-
ence of very low amounts of retinoblastoma protein
(pRB) [37]. Hence, elevated MCP-1 induction was not
masked by a potential synchronization effect, which
would increase the fraction of cells in G1 of the cell cycle
that respond to TNF-α.
To further substantiate a general effect of p53 on MCP-
1 regulation, we also used fibroblasts from Li-Fraumeni
patients, carrying a germ-line mutation in one p53 allele
during early passage, while the remaining wild-type allele
of p53 also became mutated after spontaneous immortal-
ization [34,35]. As demonstrated in Fig. 4A, cells cultured
in passage 8 still showed a significant MCP-1 induction
after TNFα treatment, which was strongly reduced when
immortalized cells at passage 160 were examined. A more
direct involvement of endogenous p53 in MCP-1 regula-
tion could also be confirmed through direct sh/siRNA
knockdown experiments either directly in E7-immortal-
ized keratinocytes (Fig. 1B) or in glioblastoma cells
(A172), where in both cases a decreased inducibility of
MCP-1 after TNF-α could be observed (Fig. 4D).
However, it should be noted that besides p53, there are
still additional transcription factors which may contrib-
ute to TNF-α mediated MCP-1 expression in certain cell
types. Previous studies have shown that both NFκB and
AP-1 are also involved in the transcriptional regulation of
MCP-1 [18-21]. DNA binding sites for both have been
characterized within the MCP-1 upstream region (Fig.
1C), but AP-1 additionally binds to a stretch of regulatory
DNA located downstream of the coding sequence [18].
Here, changes in AP-1 composition and stoichiometry
have also profound effects on non-malignant HPV-posi-
tive cells. For instance, ectopic expression of c-fos
Figure 4 Expression of MCP-1 in Li Fraumeni fibroblasts and after p53 knockdown in A172 cells. (A) RT-PCR of MCP-1 and GAPDH in Li Fraumeni 
cells (MDAH041) in passage 8 (p:8, p53 mut/wt) and passage 160 (p:160, p53 mut/mut), respectively. Cells were treated with 250 U/ml of TNF-α for 6 
h (+). Untreated control cells: (-). (B) Western blot analysis of p53 in MDAH041 cells (p:8) and (p:160) treated with TNF-α (250 U/ml) (+) for 6 h. (-): un-
treated control. Cytosolic extracts (50 μg per lane) were separated in a 12% SDS-PAGE. Actin confirms equal loading. (C) A172 cells were transiently 
transfected with pSUPER-p53 or with the empty pSUPER vector. After 24 h, cells were stimulated with TNF-α for additional 5 h. Cells were harvested 
and Western blot analysis was performed. Filters were probed with anti-p53 (DO-1) (see also panel B). (D) 4 μg of total RNA were separated in a 1% 
agarose gel and transferred to a Gene screen Plus membrane. The filter was subsequently hybridized with a MCP-1 cDNA probe. Hybridization of the 
same filter with a cDNA probe coding for the housekeeping gene β-actin confirmed equal loading. The positions of the 28S and 18S ribosomal RNA 
are indicated.
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induces tumorigenicity which also resulted in a failure of
TNF-α to induce MCP-1 [15]. This indicates that beside
p53 and its quantitative reduction in the presence of HPV
E6, AP-1 has also to be considered as a major key tran-
scription factor that regulates MCP-1 in non-malignant
HPV-positive cells.
Another interrelationship which becomes important in
this context is the cross-talk between TNF-α and p53.
TNF-α can potentially activate p53 transcription via
NFκB binding to its cognate cis-regulatory element
within the p53 promoter [30]. Moreover, the antiviral
activity of TNF-α is based on the induction of interferon-
β (IFN-β) [22], which in turn can stimulate p53 both on
transcriptional [29] and, as shown recently, also on post-
translational levels. The latter is achieved by the induc-
tion of the Interferon-Inducible gene IFIXα1, which in
turn down-regulates the human homologue of the mouse
double-minute gene 2 (mdm2) HDM2, a well-known
negative regulator of p53 stability [54]. Such a scenario
could explain why in ChIP assays p53 was only found to
interact with its binding sites within the MCP-1 regula-
tory region upon TNF-α treatment (Fig. 5). Transcrip-
tional enhancement of p53 and/or its post-translational
stabilization may compensate for lower DNA binding
affinity of p53 to the MCP-1 regulatory region as com-
pared to the p21 promoter, whose binding does not
require p53 accumulation to the same extent. Consistent
with this assumption is the finding that fractalkine, a
CX3C chemokine, is also a direct target of p53. Here,
there is a dose-dependent chemokine induction, while
Figure 5 p53 binds to the enhancer region of MCP-1 in vivo. (A) DNA sequence of the 5'-regulatory region of the MCP-1 gene (-2550 to -2250) 
indicating MCP-1 specific primer pairs used for the chromatin immunoprecipitation (ChIP) assay by arrows. The p53 binding site is marked with bold 
letters. (B) 4Bv cells were maintained at 37°C or shifted to 32°C for 5 h and stimulated with TNF-α for additional 5 h. Cells were harvested for chromatin 
immunoprecipitation (ChIP) assay as described in Materials and Methods. Samples were subjected to immunoprecipitation without antibody (no ab), 
with p53 antibody or rabbit IgG (IgG); total lysate was used as a control for PCR amplification (input). (B, left panel) p53 binding was tested by using 
MCP-1 specific primers; (B, right panel) p21 primers were used as a positive control. Untreated control cells (-); cells treated with 250 U/ml of TNF-α 
for 5 h (+).
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the steady-state level of p21 is already saturated at lower
amounts of p53 [55].
As noted above, there is in fact a functional link
between IFN-β and p53 activation, since exogenously
added IFN-β even increases p53 levels in HPV18-positive
HeLa cells despite E6/E7 expression [29]. The reason why
MCP-1 is not induced under these conditions [7-9] is due
to the AP-1 dimerization pattern, which exists in a com-
position typically found when HPV-positive cells undergo
malignant progression [9,15]. However, taking advantage
of the Li-Fraumeni cell system, TNF-α is strongly induc-
ing IFN-β (see additional file 1), which can explain
increased p53 accumulation upon cytokine application in
early passage cells (Fig. 4B). Moreover, using non-malig-
nant hybrids made between HeLa cells and human fibro-
blasts [14], where an AP-1 composition typical for
normal cells is restored after somatic cell hybridization
[9,15], both IFN-β induction and p53 increase in conjunc-
tion with MCP-1 could be discerned (see additional file
1). Tumorigenic segregants derived from the same
hybrids in turn lack this property, since MCP-1 induction
was as marginal as in late passage Li-Fraumeni cells (Fig.
4A and 4B). Hence, the cross-talk between TNF-α and
p53 is apparently mediated by IFN-β, which increases the
amount of intracellular p53 to enhance binding to its cog-
nate sequence within the MCP-1 promoter.
In addition, it is also conceivable that transcriptional
coactivators may change the local chromatin structure of
MCP-1 [56], thereby facilitating p53 binding upon TNF-α
treatment. Transcription factors such as NFκB or AP-1
can recruit and interact with coactivators such as CBP/
p300, known to possess intrinsic histone acetyltrans-
ferase (HAT) activity [57]. CBP/p300 HAT activity is reg-
ulated through phosphorylation and is targeted by
kinases after TNFα stimulation [58]. CBP/p300 can also
interact and acetylate p53, thereby increasing its DNA
binding affinity and biological activity [59]. Although pre-
vious studies have shown that p53 and NFκB may antago-
nize each other [60], they were also found to act
synergistically in the regulation of gene expression [61].
Hence, the nature of these effects may depend on
whether p53 and NFκB compete or cooperate in the
recruitment of co-activators such as CBP/p300.
Conclusions
Our data demonstrate not only a link between p53 and
MCP-1 activation, but also suggests that functional p53
inactivation, either via E6-mediated degradation in the
context of HPV-induced carcinogenesis [31] or after p53
mutation in other forms of human cancer [32], could
affect immunological surveillance by abrogating intercel-
lular communication between somatic cells and cell of
the monocyte/macrophage lineage.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KH performed experiments and wrote parts of the manuscript. BR-O: designed
and performed experiments, participated in the discussion, artwork and final
manuscript preparation. GB contributed to the ChIP experiments. SYS per-
formed parts of the EMSA experiments. BW designed and supervised the ChIP
experiments, contributed to writing of the manuscript. LW designed and
supervised EMSA experiments and wrote the corresponding part of the manu-
script. FR has designed the study, partially supervised the PhD thesis of KH and
wrote the manuscript. All authors read and approved the final version of this
manuscript.
Acknowledgements
The authors thank Moshe Oren (Weizmann Institute of Science, Rehovot, Israel) 
for providing the stable Hep3B clones and Michael Tainsky (Wayne State Uni-
versity School of Medicine, Detroit, MI 48201, USA) for providing the Li-Frau-
meni cells. The pSUPER vector system was kindly made available by Reuven 
Agami (The Netherlands Cancer Institute, Amsterdam, Netherlands). The excel-
lent technical support of Regina Ly, Nadine Gmelin and Corinna Klein is appre-
ciated. The authors thank Michael Stoehr (DKFZ, Heidelberg) for his help in 
flow cytometric analysis. We also appreciate the engagement of Patrick Finzer 
(Bioscientia, Institute for Medical Diagnostics, Moers, Germany), who was ini-
tially involved in this study. In particular his special part in the supervision of 
Katrin Hacke's PhD thesis has to be emphasized. This work was primarily sup-
ported by the Deutsche Krebshilfe, (grant 10-1983 RöI.) and partially by the 
Deutsche Forschungsgemeinschaft, (grants Wi 1376/3-1 and-2). Work done in 
the Wasylyk laboratory was financed by the CNRS, INSERM, ARC LNCC and 
INCa.
Author Details
1Deutsches Krebsforschungszentrum, Forschungsschwerpunkt Infektion und 
Krebs, Abteilung Genomveränderung und Karzinogenese, Heidelberg, 
Germany, 2Universitätsfrauenklinik, Sektion Gynäkologische Onkologie, Ulm, 
Germany, 3Institut de Génétique et de Biologie Moléculaire et Cellulaire, 
Illkirch, France, 4Deutsches Krebsforschungszentrum, Forschungsschwerpunkt 
Infektion und Krebs, Abteilung Virale Transformationsmechanismen, 
Heidelberg, Germany, 5Department of Medicine, David Geffen School of 
Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA 
and 6Dana-Faber Cancer Institute, Boston, MA 02115, USA
References
1. Gerard C, Rollins BJ: Chemokines and disease.  Nat Immunol 2001, 
2:108-115.
2. Baggiolini M, Dahinden CA: CC chemokines in allergic inflammation.  
Immunol Today 1994, 15:127-133.
3. Ransohoff RM, Glabinski A, Tani M: Chemokines in immune-mediated 
inflammation of the central nervous system.  Cytokine Growth Factor Rev 
1996, 7:35-46.
4. Huang S, Singh RK, Xie K, Gutman M, Berry KK, Bucana CD, Fidler IJ, Bar-Eli 
M: Expression of the JE/MCP-1 gene suppresses metastatic potential in 
murine colon carcinoma cells.  Cancer Immunol Immunother 1994, 
39:231-238.
Additional file 1 Expression of interferon-β, in Li Fraumeni fibroblasts 
and somatic cell hybrids made between HeLa cells and normal human 
fibroblasts. (A): RT-PCR of interferon-β (IFN-β) and GAPDH in Li Fraumeni 
cells (MDAH041) in passage 8 (p:8, p53 mut/wt) and passage 160 (p:160, 
p53 mut/mut) (see also Fig. 4A). (B): Upper panel: RT-PCR of MCP-1, inter-
feron-β (IFN-β) and GAPDH of non-malignant hybrids (referred as "444") 
and in derived tumorigenic segregants (referred as "CGL-3"). Lower panel: 
Western blot. The same filter was consecutively incubated using an anti-
p53 (DO-1) and actin antibody. (+) Cells were treated with 250 U/ml of TNF-
α for 6 h, (-) untreated control cells.
Received: 2 February 2010 Accepted: 20 April 2010 
Published: 20 April 2010
This article is available from: http://www.molecular-cancer.com/content/9/1/82 © 2010 Hacke et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular Cancer 2010, 9:82Hacke et al. Molecular Cancer 2010, 9:82
http://www.molecular-cancer.com/content/9/1/82
Page 11 of 12
5. Rollins BJ, Sunday ME: Suppression of tumor formation in vivo by 
expression of the JE gene in malignant cells.  Mol Cell Biol 1991, 
11:3125-3131.
6. Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular 
disease.  Circ Res 2004, 95:858-866.
7. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R, Rösl F: Monocyte-chemo-
attractant-protein-1 (MCP-1)-gene expression in cervical intra-
epithelial neoplasias and cervical carcinomas.  Int J Cancer 1999, 
82:6-11.
8. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, 
Munger K, Daly CM, Rösl F, Rollins BJ: Selective suppression of monocyte 
chemoattractant protein-1 expression by human papillomavirus E6 
and E7 oncoproteins in human cervical epithelial and epidermal cells.  
Int J Cancer 2003, 107:407-415.
9. Rösl F, Lengert M, Albrecht J, Kleine K, Zawatzky R, Schraven B, zur Hausen 
H: Differential regulation of the JE gene encoding the monocyte 
chemoattractant protein (MCP-1) in cervical carcinoma cells and 
derived hybrids.  J Virol 1994, 68:2142-2150.
10. zur Hausen H: Papillomaviruses and cancer: from basic studies to 
clinical application.  Nat Rev Cancer 2002, 2:342-350.
11. Tindle RW: Immune evasion in human papillomavirus-associated 
cervical cancer.  Nat Rev Cancer 2002, 2:59-65.
12. Merlo LM, Pepper JW, Reid BJ, Maley CC: Cancer as an evolutionary and 
ecological process.  Nat Rev Cancer 2006, 6:924-935.
13. Kanodia S, Fahey LM, Kast WM: Mechanisms used by human 
papillomaviruses to escape the host immune response.  Curr Cancer 
Drug Targets 2007, 7:79-89.
14. Stanbridge EJ: Genetic analysis of human malignancy using somatic 
cell hybrids and monochromosome transfer.  Cancer Surv 1988, 
7:317-324.
15. Soto U, Das BC, Lengert M, Finzer P, zur Hausen H, Rösl F: Conversion of 
HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive 
growth involves loss of TNF-alpha mediated repression of viral 
transcription and modification of the AP-1 transcription complex.  
Oncogene 1999, 18:3187-3198.
16. Riethdorf L, Riethdorf S, Gutzlaff K, Prall F, Loning T: Differential 
expression of the monocyte chemoattractant protein-1 gene in 
human papillomavirus-16-infected squamous intraepithelial lesions 
and squamous cell carcinomas of the cervix uteri.  Am J Pathol 1996, 
149:1469-1476.
17. Spinillo A, Tenti P, Zappatore R, De Seta F, Silini E, Guaschino S: 
Langerhans' cell counts and cervical intraepithelial neoplasia in 
women with human immunodeficiency virus infection.  Gynecol Oncol 
1993, 48:210-213.
18. Finzer P, Soto U, Delius H, Patzelt A, Coy JF, Poustka A, zur Hausen H, Rosl F: 
Differential transcriptional regulation of the monocyte-
chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-
tumorigenic HPV 18 positive cells: the role of the chromatin structure 
and AP-1 composition.  Oncogene 2000, 19:3235-3244.
19. Ping D, Jones PL, Boss JM: TNF regulates the in vivo occupancy of both 
distal and proximal regulatory regions of the MCP-1/JE gene.  Immunity 
1996, 4:455-469.
20. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T: Transcriptional regulation 
of the human monocyte chemoattractant protein-1 gene. Cooperation 
of two NF-kappaB sites and NF-kappaB/Rel subunit specificity.  J Biol 
Chem 1997, 272:31092-31099.
21. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, 
Kawamoto S, Ishigatsubo Y, Okubo T: NF-kappa B and Sp1 regulate 
transcription of the human monocyte chemoattractant protein-1 
gene.  J Immunol 1994, 153:2052-2063.
22. Bachmann A, Hanke B, Zawatzky R, Soto U, van Riggelen J, zur Hausen H, 
Rosl F: Disturbance of tumor necrosis factor alpha-mediated beta 
interferon signaling in cervical carcinoma cells.  J Virol 2002, 76:280-291.
23. Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of 
infectious diseases.  Crit Care Med 1993, 21:S423-435.
24. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor 
superfamilies: integrating mammalian biology.  Cell 2001, 104:487-501.
25. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation.  
Science 1998, 281:1305-1308.
26. Gatz SA, Wiesmuller L: p53 in recombination and repair.  Cell Death Differ 
2006, 13:1003-1016.
27. Haffner R, Oren M: Biochemical properties and biological effects of p53.  
Curr Opin Genet Dev 1995, 5:84-90.
28. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, Garcia-
Sastre A, Lee SW, Aaronson SA: Transcriptional role of p53 in interferon-
mediated antiviral immunity.  J Exp Med 2008, 205:1929-1938.
29. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, 
Imai K, Shibue T, Honda K, Taniguchi T: Integration of interferon-alpha/
beta signalling to p53 responses in tumour suppression and antiviral 
defence.  Nature 2003, 424:516-523.
30. Wu H, Lozano G: NF-kappa B activation of p53. A potential mechanism 
for suppressing cell growth in response to stress.  J Biol Chem 1994, 
269:20067-20074.
31. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and 
E6-AP complex functions as a ubiquitin-protein ligase in the 
ubiquitination of p53.  Cell 1993, 75:495-505.
32. Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer 
implications.  Nat Rev Cancer 2009, 9:95-107.
33. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, Eichhorst ST, zur Hausen H, 
Krammer PH, Rösl F: Restoration of p53 expression sensitizes human 
papillomavirus type 16 immortalized human keratinocytes to CD95-
mediated apoptosis.  Oncogene 2002, 21:165-175.
34. Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC, 
Tainsky MA: Tumorigenic transformation of spontaneously 
immortalized fibroblasts from patients with a familial cancer 
syndrome.  Oncogene 1991, 6:183-186.
35. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong 
LC, Tainsky MA: Spontaneous abnormalities in normal fibroblasts from 
patients with Li-Fraumeni cancer syndrome: aneuploidy and 
immortalization.  Cancer Res 1990, 50:7979-7984.
36. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA: Epigenetic 
silencing of multiple interferon pathway genes after cellular 
immortalization.  Oncogene 2003, 22:4118-4127.
37. Friedman SL, Shaulian E, Littlewood T, Resnitzky D, Oren M: Resistance to 
p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells.  
Oncogene 1997, 15:63-70.
38. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of 
short interfering RNAs in mammalian cells.  Science 2002, 296:550-553.
39. Rollins BJ, Stier P, Ernst T, Wong GG: The human homolog of the JE gene 
encodes a monocyte secretory protein.  Mol Cell Biol 1989, 9:4687-4695.
40. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, 
Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 
tumor suppression.  Cell 1993, 75:817-825.
41. Eick D, Bornkamm GW: Transcriptional arrest within the first exon is a 
fast control mechanism in c-myc gene expression.  Nucleic Acids Res 
1986, 14:8331-8346.
42. Stohr M, Vogt-Schaden M, Knobloch M, Vogel R, Futterman G: Evaluation 
of eight fluorochrome combinations for simultaneous DNA-protein 
flow analyses.  Stain Technol 1978, 53:205-215.
43. Dean PN, Jett JH: Mathematical analysis of DNA distributions derived 
from flow microfluorometry.  J Cell Biol 1974, 60:523-527.
44. Dudenhoffer C, Kurth M, Janus F, Deppert W, Wiesmuller L: Dissociation 
of the recombination control and the sequence-specific 
transactivation function of P53.  Oncogene 1999, 18:5773-5784.
45. Dudenhoffer C, Rohaly G, Will K, Deppert W, Wiesmuller L: Specific 
mismatch recognition in heteroduplex intermediates by p53 suggests 
a role in fidelity control of homologous recombination.  Mol Cell Biol 
1998, 18:5332-5342.
46. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of 
a consensus binding site for p53.  Nat Genet 1992, 1:45-49.
47. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein 
B: Oncogenic forms of p53 inhibit p53-regulated gene expression.  
Science 1992, 256:827-830.
48. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD: ATM-dependent 
activation of p53 involves dephosphorylation and association with 14-
3-3 proteins.  Nat Genet 1998, 19:175-178.
49. Ory K, Legros Y, Auguin C, Soussi T: Analysis of the most representative 
tumour-derived p53 mutants reveals that changes in protein 
conformation are not correlated with loss of transactivation or 
inhibition of cell proliferation.  EMBO J 1994, 13:3496-3504.
50. Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling.  
Cell Death Differ 2003, 10:45-65.Hacke et al. Molecular Cancer 2010, 9:82
http://www.molecular-cancer.com/content/9/1/82
Page 12 of 12
51. Varley JM: Germline TP53 mutations and Li-Fraumeni syndrome.  Hum 
Mutat 2003, 21:313-320.
52. Donehower LA, Bradley A: The tumor suppressor p53.  Biochim Biophys 
Acta 1993, 1155:181-205.
53. Liu PK, Kraus E, Wu TA, Strong LC, Tainsky MA: Analysis of genomic 
instability in Li-Fraumeni fibroblasts with germline p53 mutations.  
Oncogene 1996, 12:2267-2278.
54. Ding Y, Lee JF, Lu H, Lee MH, Yan DH: Interferon-inducible protein 
IFIXalpha1 functions as a negative regulator of HDM2.  Mol Cell Biol 
2006, 26:1979-1996.
55. Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa 
M, Nakamura Y, Arakawa H: Identification of fractalkine, a CX3C-type 
chemokine, as a direct target of p53.  Cancer Res 2000, 60:3722-3726.
56. Boekhoudt GH, Guo Z, Beresford GW, Boss JM: Communication between 
NF-kappa B and Sp1 controls histone acetylation within the proximal 
promoter of the monocyte chemoattractant protein 1 gene.  J Immunol 
2003, 170:4139-4147.
57. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T: CREB-
binding protein/p300 are transcriptional coactivators of p65.  Proc Natl 
Acad Sci USA 1997, 94:2927-2932.
58. Ait-Si-Ali S, Carlisi D, Ramirez S, Upegui-Gonzalez LC, Duquet A, Robin P, 
Rudkin B, Harel-Bellan A, Trouche D: Phosphorylation by p44 MAP 
Kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro.  
Biochem Biophys Res Commun 1999, 262:157-162.
59. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by 
acetylation of the p53 C-terminal domain.  Cell 1997, 90:595-606.
60. Webster GA, Perkins ND: Transcriptional cross talk between NF-kappaB 
and p53.  Mol Cell Biol 1999, 19:3485-3495.
61. Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A, 
Taniere P, Chariot A, Scoazec JY, de Moura Gallo CV, et al.: Transcriptional 
activation of cyclooxygenase-2 by tumor suppressor p53 requires 
nuclear factor-kappaB.  Oncogene 2006, 25:5708-5718.
doi: 10.1186/1476-4598-9-82
Cite this article as: Hacke et al., Regulation of MCP-1 chemokine transcrip-
tion by p53 Molecular Cancer 2010, 9:82